Interventional Clinical Trial Evaluating COVER PATCH CAPTEUR PROTECT Support Solutions for Continuous Glucose Monitoring Sensors in Patients With Diabetes
This study tests a special adhesive patch called COVER PATCH that is designed to help continuous glucose monitoring (CGM) sensors stay attached to your skin better. CGM sensors measure your blood sugar levels throughout the day and night, and keeping them securely in place is important for getting accurate readings to help manage your diabetes.
Key Objective: The trial is testing whether the COVER PATCH can improve how well continuous glucose monitors stick to the skin, potentially reducing sensor failures and improving the reliability of blood sugar readings.
Who to Consider: People with diabetes who use continuous glucose monitoring sensors and experience problems with sensor adhesion or frequent sensor detachment should consider enrolling.
Trial Parameters
Brief Summary
The aim of this clinical trial is to evaluate whether the COVER PATCH adhesive patch can improve the adhesion of continuous glucose monitors (CGMs). CGMs provide continuous blood sugar readings throughout the day and night, providing valuable data to help individuals manage their diabetes more efficiently. Many people face difficulties in keeping their CGM sensor in place. Factors such as sweat, physical activity, heat, skin creams, and swimming can cause the sensor to fall off prematurely, interrupting glucose monitoring and making it harder to maintain stable blood sugar levels. It has been shown that wearing a CGM sensor for at least 70% of the time is linked to better blood sugar control, measured by lower glycated hemoglobin (HbA1c). HbA1c reflects the average blood sugar over the past 3 months. A lower HbA1c level is associated with better diabetes management. Currently, CGM sensors are designed for one-time use and need to be replaced every 7 to 15 days. However, when sensors fall off prematurely, they need to be replaced more frequently, leading to higher costs for patients. This can exceed what is covered by insurance. Some patients use non-approved solutions, like extra adhesive tapes, to keep their sensors in place, but these methods may not be effective. This clinical trial aims to answer the following questions: * Does the adhesive patch help keep the CGM sensor in place for the full recommended duration? * Does better sensor adhesion lead to improved blood sugar control and lower HbA1c? * Does the patch help reduce the frequency of premature sensor replacements? To take part in this study, participants must be at least 6 years old and have type 1 or type 2 diabetes. Participants continue using their usual CGM during the study and are randomly assigned to either use the adhesive patch (COVER PATCH) or not. Participants and/or their parents (depending on the participant's age) complete questionnaires at the start of the study, and again at the end of the study at 4 months. Throughout the 4-month period, they also use an electronic tool (ePRO) to record each CGM sensor change and the reason for replacement. This study may help improve how well glucose sensors stay in place, reduce the need to change them too often, and make it easier to manage blood sugar. It also aims to fulfill a medical need that is currently not adequately covered.
Eligibility Criteria
Inclusion Criteria: * Male or female * At least 6 years old * Diagnosed with type 1 or type 2 diabetes * Currently using a continuous glucose monitoring (CGM) sensor * CGM sensor usage time \< 70% over the last 4 months * HbA1c ≥ 8% (verified by blood test or capillary test, no older than one month at the time of enrollment) * Patient (or legal representative) owns a smartphone and has internet access (for completing questionnaires) * Patient is covered by a social security scheme * Patient (or legal representative, if applicable) is capable of reading and understanding the study procedure, and is able to give informed consent for participation in the study protocol Exclusion Criteria: * Patient with serious and untreated skin issues in the areas where the device will be applied (e.g., psoriasis, herpetiform dermatitis, skin rash, staphylococcal infection, etc.) * Patient currently participating or having participated in an interventional clinical study within the month prior to enroll